BioStock: Chordate's CSO comments on the start of the PM009 study

The first patient has now been enrolled in Chordate Medical's open pilot study PM009, which aims to evaluate the effect of the company's migraine treatment Ozilia on patients who do not respond to treatment with CGRP inhibitors and other treatment options. BioStock reached out to the company's Clinical Research & Medical Director, Jan Hermansson, to find out more about the study. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/12/chordates-cso-comments-on-the-start-of-the-pm009-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se